The FDA has denied a petition for qualified health claims linking green tea or its extract to reduced cardiovascular disease (CVD) risk factors, citing a lack of credible scientific evidence. The denial has sparked discussions about the implications for the petitioner, who may regret seeking the claim, as it could undermine public perception of green tea's health benefits. While the FDA's rejection pertains specifically to CVD claims, it does not negate the possibility of other health benefits from green tea, which could be explored through separate applications. Critics of the FDA often overlook that the agency reviews evidence submitted by claimants rather than conducting studies itself. The process requires demonstrable safety and efficacy at the doses provided, which must be proven to support any health claims. Concerns about the FDA's thoroughness are noted, but personal experiences suggest that its rigorous standards ensure reliable research outcomes.